XENOGRAFT
MODELS
DOMESTIC QUALITY at COMPETITIVE PRICES
When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices
PERSONAL TOUCH
We love our clients! We are flexible and easy to work with. And we take a personal interest in our clients' studies.
Xenograft models entail the implantation of human cancer cells into a host animal, typically an immunocompromised mouse or rat. Xenograft tumor models are effective tools for assessing in vivo efficacy of candidate cancer drugs.
Other options include:
-
Custom xenograft study designs
-
Fluorescent imaging
-
MTD studies
-
Pre-clinical drug formulation
-
Tumor collection, organ collection, histology
-
Pharmacodynamic studies (e.g. ELISA, Luminex, PCR, sequencing, flow cytometry)
Please see below for our available models or to request a quote
XENOGRAFT
cell lines
Cell line | Organ | Mutations | Weeks from stratification to termination (average) | Growth Curve |
|---|---|---|---|---|
22Rv1 | Prostate | KMT2D, PIK3CA, TP53 | 5 | |
786-0 | Renal | PTEN, TERT, TP53, VHL | N/A | |
A-375 | Skin | BRAF, CDKN2A, TERT | 4 | |
A431 | Skin | TP53, EGFR-PPARGC1A fussion | N/A | |
A498 | Renal | PIK3CB, VHL | 5 | |
A549 | Lung | KRAS, STK11, TP53 | 6 | |
A673 | Sarcoma | BRAF, TP53, EWS-FLI1 fusion | 3 | |
AGS | Gastric | CTNNB1, KRAS, PIK3CA, TP53 | 6 | |
BxPc-3 | Pancreatic | BRAF, KRAS, TP53 | 7 | |
CHLA-06 | Brain | TP53 | 6 | |
Caki-1 | Renal | RB1 | 4 | |
Colo-205 | Colon | APC, BRAF, CTNNB1, TP53 | 2.5 | |
DLD-1 | Colon | APC, ACVR2A, B2M, EP300, KRAS, PIK3CA, TGFBR2, TP53 | 4 | |
DU-145 | Prostate | CDKN2A, RB1, STK11, TP53 | 6 | |
ES-2-luc | Ovarian | BRAF, PALB2, TERT, TP53 | 3.5 | |
HCC1954 | Breast | PIK3CA, TP53, CLTC-VMP1 fusion | 7 | |
HCT-116 | Colon | ACVR2A, BRCA2, CDKN2A, CTNNB1, EP300, KRAS, PIK3CA, PPM1D, TGFBR2, TP53 | 5 | |
HT-29 | Colon | APC, BRAF, PIK3CA, SMAD4, TP53 | N/A | |
HuCCT1 | Bile Duct | KRAS, MSH6, TP53 | 5 | |
Huh-7 | Liver | KDR, POLD3, TERT, TP53 | 4 | |
JIMT-1 | Breast | PIK3CA, TP53 | 8 | |
JeKo-1 | Blood | TP53 | 5 | |
LASCPC-01 | Prostate | Unavailable | 3 | |
LNCaP | Prostate | AR, MEN1, PIK3R1, PTEN, TP53 | 4 | |
MDA-MB-231 | Breast | CDKN2A, CDKN2B, BRAF, KRAS, TERT, TP53 | 4 | |
MDA-MB-468 | Breast | PTEN, RB1, TP53 | N/A | |
MIAPaCa-2 | Pancreatic | KRAS, TP53 | 8 | |
MOLM-13 | Blood | FLT3, KMT2A-MLLT3 fusion | 14 | |
NCI-H1703 | Lung | CDKN2A, TP53 | 3 | |
NCI-H1975 | Lung | EGFR, PIK3CA, TP53 | 6 | |
NCI-H460 | Lung | KRAS, PIK3CA, STK11, TP53 | 5 | |
NCI-N87 | Gastric | ERBB3, TP53 | 6 | |
OCI-AML-3 | Blood | DNMT3A, NRAS, NPM1 | 2 | |
OCI-Ly1 | Blood | Unavailable | N/A | |
OVCAR8 | Ovarian | CTNNB1, ERBB2, KRAS, TP53 | 8 | |
PANC-1 | Pancreatic | KRAS, TP53 | 3 | |
PC-3 | Prostate | TP53 | 4 | |
SK-BR-3 | Breast | TP53 | 4 | |
SK-N-FI | Brain | NF1, TP53 | 4 | |
SK-N-MC | Sarcoma | TP53, EWS-FLI1 fusion | 3 | |
SK-OV-3 | Ovarian | APC, FBXW7, PIK3CA, TP53 | 10 | |
SKM-1 | Blood | ASXL1, BCORL1, EZH2, KRAS, TP53 | 3 | |
SU-DHL-16 | Blood | Unavailable | 4 | |
SW480 | Colon | APC, KRAS, TP53 | 4 | |
TT | Thyroid | RET, TBX3 | 4 | |
U-87MG | Brain | Unavailable | 3 | |
U118-MG | Brain | IDH1, PTEN, TP53 | 6 | |
UM-UC-3 | Bladder | KRAS, PARD3B, TERT, TP53 | N/A | |
VcAP | Prostate | MLH1, TP53, TMPRss2-ERG fusion | N/A | |
WITT (SK-Cha-1) | Bile Duct | Unavailable | N/A | |
WM164 | Skin | BRAF | 6 | |
YAPC | Pancreatic | KRAS, TP53 | N/A |
*Other cell lines are possible, please contact us about your cell line of choice
QUOTE REQUEST FORM
xenograft studies
Please fill out the form below
We will respond with a quote within one business day
MEET OUR SCIENTIFIC DIRECTOR
Bret Stephens, PhD
Dr. Stephens has a broad in vivo biology background that comes from twenty years of involvement in cancer drug discovery in both academic and pharmaceutical industry settings.
Dr. Stephens received his PhD in Molecular Biology from the University of Arizona.
Previous to joining Rincon Bio, Dr. Stephens worked at Tolero Pharmaceuticals, Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on cancer small molecule drug development.
ABOUT US
Founded in 2013, Rincon Bio is a pre-clinical CRO focusing on in vivo cancer efficacy studies, both allogeneic (human cell models) and syngeneic (immunotherapy models).
The staff at Rincon Bio have performed hundreds of efficacy studies for pharmaceutical researchers across the United States and Europe, both in industry and in academia. We've worked in the world of small, agile, start-up pharma, which gives us a unique perspective as a CRO. We appreciate that your priorities change quickly, and you need a partner that can adapt along with you. Furthermore, we can initiate most efficacy studies more quickly than any other CRO.
We understand the importance of transparency and communication: at Rincon Bio, our clients are assigned a single point-of-contact, who is responsible for managing their study from conception to completion.
Rincon Bio is a US-based organization, born from a desire to simplify the process of running cancer efficacy studies, and to provide domestic quality at competitive prices. We are The Cancer Model CRO - we believe in doing one thing, and doing it well.
If you do decide to run your study at Rincon Bio, the process will be easy, streamlined, and pleasant.
Email: info@rinconbio.com
Tel: 760-713-6613
Utah:
3900 N Traverse Mountain Blvd
Suite 100
Lehi, UT 84043
California:
3156 Vista Way, Suite 220
Oceanside, CA 92056